Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

4.170 UNCHANGED

Streaming Delayed Price Updated: 4:15 PM EDT, Apr 9, 2026 Add to My Watchlist

Price and Volume

Volume	8
Open	4.170
Bid (Size)	4.100 (3,000)
Ask (Size)	4.290 (100)
Prev. Close	4.170
Today's Range	4.170 - 4.170
52wk Range	2.120 - 7.550
Shares Outstanding	38,886,465
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline

April 09, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST

April 07, 2026

From Pomerantz LLP

Via GlobeNewswire

Performance

YTD	-35.3%	-35.3%
1 Month	-0.7%	-0.7%
3 Month	-32.9%	-32.9%
6 Month	-37.7%	-37.7%
1 Year	+61.6%	+61.6%

More News

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)

April 07, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline

April 02, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

April 02, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST

March 31, 2026

From Pomerantz LLP

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)

March 31, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before Upcoming Lead Plaintiff Deadline

March 30, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

March 30, 2026

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST

March 29, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline

March 26, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026

March 25, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST

March 24, 2026

From Pomerantz LLP

Via GlobeNewswire

AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & Korsinsky

March 24, 2026

From Levi & Korsinsky, LLP

Via Business Wire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)

March 24, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST

March 22, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

March 20, 2026

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline

March 19, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

AQST CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026

March 18, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST

March 17, 2026

From Pomerantz LLP

Via GlobeNewswire

AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky

March 17, 2026

From Levi & Korsinsky, LLP

Via Business Wire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)

March 17, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

AQST UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

March 14, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST

March 13, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline

March 12, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Frequently Asked Questions

Is Aquestive Therapeutics, Inc. - Common Stock publicly traded?

Yes, Aquestive Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Aquestive Therapeutics, Inc. - Common Stock trade on?

Aquestive Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Aquestive Therapeutics, Inc. - Common Stock?

The ticker symbol for Aquestive Therapeutics, Inc. - Common Stock is AQST on the Nasdaq Stock Market

What is the current price of Aquestive Therapeutics, Inc. - Common Stock?

The current price of Aquestive Therapeutics, Inc. - Common Stock is 4.170

When was Aquestive Therapeutics, Inc. - Common Stock last traded?

The last trade of Aquestive Therapeutics, Inc. - Common Stock was at 04/09/26 04:15 PM ET

What is the market capitalization of Aquestive Therapeutics, Inc. - Common Stock?

The market capitalization of Aquestive Therapeutics, Inc. - Common Stock is 162.16M

How many shares of Aquestive Therapeutics, Inc. - Common Stock are outstanding?

Aquestive Therapeutics, Inc. - Common Stock has 162M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.